Resonance Health Ltd · ASX:RHT
Resonance Health — Shareholder Meeting (November 2025)
13 slides from Resonance Health's shareholder meeting presentation, Nov 13, 2025
Slide 1: Resonance Health Annual General Meeting
Resonance Health Annual General Meeting 13 November 2025 Andrew Harrison MD & CEO 1 1
Slide 2: Business transformation well underway
Business transformation well underway *Normalised Operating EBITDA = Statutory Net Loss – (R&D tax Credit, FX gain, Share based payments) + (Depreciation, amortisation & net interest expense, one-off restructuring & transaction costs, and unearned income). 2
Slide 3: Significant revenue growth and diversification since FY23
Significant revenue growth and diversification since FY23 FY26 FY23 ü FY23–FY26 strong revenue growth (~45% CAGR) ü Profitable ~$2M EBITDA ü Diversified revenue ü Customer, clinical, and technical Total Revenue $4.4M synergies Total Revenue Guidance ~$17M 3
Slide 4: We have significantly expanded our addressable global market
We have significantly expanded our addressable global market… + CRO and Investigator site services ~$70b New Imaging Endpoints for + obesity and liver fibrosis Metabolic & Obesity VAT, SAT, MRE >$500m + liver fat market ~$300m + MRI Liver Iron 2023 Measurement market ~ $200M 4
Slide 5: More Customers
The strategy of getting a greater “share of wallet” expands on 3 vectors, more therapeutic areas, more services to each customer, and more customers through organic or acquisitive growth. More sites – Geographic (Australia then overseas) More phases – Later stage to Phase 1 More Customers More Custo
Slide 6: Growth strategy bears early fruit
Growth strategy bears early fruit… Therapeutic Services (cross-selling) Area First Liver / Spleen Iron, then Site services - Australian global Haematology TrialsWest pharma Work Won First Liver / Spleen Iron, then central reading US global pharma Haematology & image storage First CRO, then Site serv
Slide 7: While oncology dominates the global trial landscape, there is rapid growth in other therapeutic areas
While oncology dominates the global trial landscape, there is rapid growth in other therapeutic areas… 7
Slide 8: In the metabolic diseases space rapid growth is being driven by GLP-1-like drugs
In the metabolic diseases space rapid growth is being driven by GLP-1-like drugs 8
Slide 9: Resonance's deep expertise in liver and related metabolic / obesity areas meets a significant opportunity
Resonance’s deep expertise in liver and related metabolic / obesity areas meets a significant opportunity… 9
Slide 10: Growth Opportunities
Our clinical trial customers are global pharma. Trial protocols are standardized across trials globally and are run according to GCP. This makes Resonances’ expansion geographically agnostic and presents a medium-term growth opportunity Growth Opportunities SaMD Business ü More devices to existing &
Slide 11: FY26 Guidance Maintained
FY26 Guidance Maintained FY26 Guidance $M Revenue 17 Underlying Operating EBITDA 2 ü Solid trading in first quarter in line with expectations ü Grow underlying EBITDA margins to ~12%. Target EBITDA margins over coming periods ~25% as operational leverage drives margin expansion ü Operationally cashf
Slide 12: Disclaimer Forward Looking Statements
Disclaimer Forward Looking Statements This presentation has been prepared by Resonance Health Ltd (“Resonance Health” or “Company”) and may contain forward-looking statements that are based on current expectations and beliefs and are subject to numerous factors and uncertainties that could cause act
Slide 13: resonance-health-ltd/
Resonance i fh) esonance-health-Itd/
Resonance Health — Shareholder Meeting (November 2025) on 6ix